Skip to main content
. 2021 Dec 18;107(5):1441–1460. doi: 10.1210/clinem/dgab888

Figure 3.

Figure 3.

Recommendations for management of antiresorptive agent-related osteonecrosis of the jaw in patients taking bone-modifying agents (BMA). Staging of antiresorptive agent-related osteonecrosis of the jaw according to the American Association of Oral and Maxillofacial Surgeons (2014). ONJ, osteonecrosis of the jaw; RCT, randomized controlled trial. *In the absence of RCT.